openPR Logo
Press release

Exosomes Therapeutic Pipeline Assessment, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trial Activities, Emerging Therapies, Treatment Algorithm, and Key Companies by DelveInsight

12-06-2022 11:10 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Exosomes Therapeutic Pipeline

Exosomes Therapeutic Pipeline

As per DelveInsight's assessment, about 55+ prominent pharma and biotech giants are actively working on 70+ drugs in the Exosomes' therapeutics market globally.

Exosomes possess a higher therapeutic potential for various disease spectra due to their ability for intracellular shuttling. Nanomedicine technologies have given rise to exploring the usage of the pathogenic importance of exosomal particles in various diseases. The increase in the usage of exosomes is a direct consequence of the overall increase in the incident and prevalent population of the diseases where they are used, along with robust R&D leading to the introduction of new exosomes for therapeutic as well as diagnostic usage, accompanied by increasing availability of exosomes.

"Exosomes Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Exosomes Therapeutics Market.

The report provides a detailed description of the pipeline drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Exosomes Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing Exosomes drugs.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development in the Exosomes segment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details in the Exosomes market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Delveinsight's Report Covers the 70+ Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/exosomes-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Exosomes Therapeutics Market Landscape
Exosomes are a type of extracellular vesicle, a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages that contain constituents (protein, DNA, and RNA) of the cells that secrete them. Exosomes contain several molecules such as microRNA (miRNA), which mediate biological functions by controlling the genes. Exosomes carrying miRNA or other molecules can, therefore, improve the therapeutic effects of various transplants that take place.

Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes have therapeutic potential to control many diseases, along with aiding in disease diagnosis. Extensive studies are going on to assess the role of exosomes in diagnosing and treating various pathologies. There are approx. 55+ key companies which are developing the Exosomes. Currently, Direct Biologics has its Exosomes drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Exosomes Market Landscape Include:
- Direct Biologics
- Capricor
- Regeneus
- AVEM HealthCare
- Aegle Therapeutics
- Organicell Regenerative Medicine
- Codiak Biosciences
- United Therapeutics
- ArunA Biomedical
- Evox Therapeutics
- MolecuVax
- Versatope Therapeutics
- Lamellar Biomedical
- Azymus Therapeutics
- Alxerion Biotech
- Avalon GloboCare
- Capricor Therapeutics
And many more

Exosomes Pipeline Products Covered in the Report Include
- ExoFlo: Direct Biologics
- Progenza: Regeneus
- AVA-201: Avalon GloboCare
- RGLS4326: Regulus Therapeutics Inc.
- exoIL-12: Codiak BioSciences
- DB-001: Direct Biologics, LLC
- AGLE 102: Aegle Therapeutics
- CAP-1002: Capricor Inc.
And many others

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/exosomes-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Introduction
2. Executive Summary
3. Exosomes: In-depth Overview
4. Pipeline Therapeutics & Comparative Analysis
5. Therapeutic Assessment
6. Exosomes - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment (Collaborations, Licensing/Partnering, Acquisition -Deal Value Trends)
8. Late-Stage Products (Phase III)
9. Mid-Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Pre-clinical and Discovery Stage Products
12. Inactive Products
13. Exosomes Key Companies
14. Exosomes Key Products
15. Exosomes Unmet Needs
16. Exosomes- Market Drivers and Barriers
17. Exosomes Future Perspectives and Conclusion
18. Exosomes Analyst Views
19. Appendix
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/exosomes-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exosomes Therapeutic Pipeline Assessment, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trial Activities, Emerging Therapies, Treatment Algorithm, and Key Companies by DelveInsight here

News-ID: 2836134 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Exosomes

Exosomes Researh: the Southeast Asia Exosomes market size is projected to reach …
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Exosomes- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market
Exosomes Development and Exosomes Manufacturing Market Key Players Analysis - 10 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment
Exosomes Development and Exosomes Manufacturing Market Know the Scope and Trends
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment
Exosomes Development and Exosomes Manufacturing Market expected to Witness Huge …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment
Exosomes Development and Exosomes Manufacturing Market Top Companies Study - 01 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment
exosomes development and exosomes manufacturing market Revenue Report with Forec …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Exosomes Development and Exosomes Manufacturing Market"- by Types of Service(s) Offered (Isolated Exosomes, Exosome Characterization, Purification, Chromatography, Engineering, Targeted Delivery, Diagnostic Biomarker, and Quality Control), Method of Exosome Manufacturing (Engineering and Targeted Delivery), Scale of Operation (Discovery / Research, Pre-Clinical, Clinical or Commercialized) and Scalability (Small, Mid-Sized or large) Trends, and Global Forecasts, 2022-2035 And Segment